# RDEA3170 and Febuxostat Drug Interaction Study

> **NCT01883167** · PHASE1 · COMPLETED · sponsor: **Ardea Biosciences, Inc.** · enrollment: 21 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** RDEA3170 10 mg
- **DRUG:** Febuxostat 40 mg
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01883167
- **Lead sponsor:** Ardea Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06
- **Primary completion:** 2013-09
- **Final completion:** 2013-12
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2014-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01883167

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01883167, "RDEA3170 and Febuxostat Drug Interaction Study". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01883167. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*